JP2022527473A5 - - Google Patents
Info
- Publication number
- JP2022527473A5 JP2022527473A5 JP2021557634A JP2021557634A JP2022527473A5 JP 2022527473 A5 JP2022527473 A5 JP 2022527473A5 JP 2021557634 A JP2021557634 A JP 2021557634A JP 2021557634 A JP2021557634 A JP 2021557634A JP 2022527473 A5 JP2022527473 A5 JP 2022527473A5
- Authority
- JP
- Japan
Links
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2025031086A JP2025098027A (ja) | 2019-03-28 | 2025-02-28 | アンチセンスを用いてがんを治療するための方法 |
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201962825516P | 2019-03-28 | 2019-03-28 | |
| US62/825,516 | 2019-03-28 | ||
| PCT/US2020/025217 WO2020198587A1 (en) | 2019-03-28 | 2020-03-27 | Methods for treating cancers using antisense |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2025031086A Division JP2025098027A (ja) | 2019-03-28 | 2025-02-28 | アンチセンスを用いてがんを治療するための方法 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2022527473A JP2022527473A (ja) | 2022-06-02 |
| JPWO2020198587A5 JPWO2020198587A5 (https=) | 2023-04-04 |
| JP2022527473A5 true JP2022527473A5 (https=) | 2023-04-04 |
Family
ID=72609134
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2021557634A Pending JP2022527473A (ja) | 2019-03-28 | 2020-03-27 | アンチセンスを用いてがんを治療するための方法 |
| JP2025031086A Pending JP2025098027A (ja) | 2019-03-28 | 2025-02-28 | アンチセンスを用いてがんを治療するための方法 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2025031086A Pending JP2025098027A (ja) | 2019-03-28 | 2025-02-28 | アンチセンスを用いてがんを治療するための方法 |
Country Status (7)
| Country | Link |
|---|---|
| US (1) | US20220195440A1 (https=) |
| EP (1) | EP3946287A4 (https=) |
| JP (2) | JP2022527473A (https=) |
| AU (1) | AU2020244865A1 (https=) |
| CA (1) | CA3134969A1 (https=) |
| MX (1) | MX2021011760A (https=) |
| WO (1) | WO2020198587A1 (https=) |
Families Citing this family (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN108291227A (zh) | 2015-10-14 | 2018-07-17 | 拜奥-帕斯控股股份有限公司 | 用于脂质体制剂的对乙氧基核酸 |
| AU2017325971A1 (en) | 2016-09-16 | 2019-04-11 | Bio-Path Holdings, Inc. | Combination therapy with liposomal antisense oligonucleotides |
| EA201992485A1 (ru) | 2017-04-19 | 2020-02-17 | Байо-Пат Холдингз, Инк. | Р-этокси нуклеиновые кислоты для ингибирования stat3 |
| EA201992490A1 (ru) | 2017-04-19 | 2020-03-03 | Байо-Пат Холдингз, Инк. | Р-этокси нуклеиновые кислоты для ингибирования bcl2 |
| WO2024077130A1 (en) * | 2022-10-05 | 2024-04-11 | Thomas Jefferson University | Methods and compositions for treating bladder cancer |
Family Cites Families (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6541036B1 (en) * | 1997-05-29 | 2003-04-01 | Thomas Jefferson University | Treatment of tumors with oligonucleotides directed to insulin-like growth factor-I receptors (IGF-IR) |
| WO2002027019A1 (en) * | 2000-09-29 | 2002-04-04 | The Johns Hopkins University School Of Medicine | Method of predicting the clinical response to chemotherapeutic treatment with alkylating agents |
| NZ554831A (en) * | 2004-11-09 | 2009-10-30 | Schering Corp | Improved dosing regimen of temozolomide for treating cancer based on the patientÆs MGMT level |
| EP1900825A1 (en) * | 2006-09-13 | 2008-03-19 | Rheinische Friedrich-Wilhelms-Universität Bonn | Sensitive and reproducible method for the determination of MGMT promoter methylation in clinical samples |
| CA2783665A1 (en) * | 2010-03-03 | 2011-09-09 | OSI Pharmaceuticals, LLC | Biological markers predictive of anti-cancer response to insulin-like growth factor-1 receptor kinase inhibitors |
| WO2016164916A1 (en) * | 2015-04-10 | 2016-10-13 | Thomas Jefferson University | Methods and compositions for treating cancers and enhancing therapeutic immunity by selectively reducing immunomodulatory m2 monocytes |
| US10357509B2 (en) * | 2017-03-09 | 2019-07-23 | Thomas Jefferson University | Methods and compositions for treating cancers using antisense |
-
2020
- 2020-03-27 MX MX2021011760A patent/MX2021011760A/es unknown
- 2020-03-27 JP JP2021557634A patent/JP2022527473A/ja active Pending
- 2020-03-27 AU AU2020244865A patent/AU2020244865A1/en active Pending
- 2020-03-27 CA CA3134969A patent/CA3134969A1/en active Pending
- 2020-03-27 US US17/599,023 patent/US20220195440A1/en active Pending
- 2020-03-27 EP EP20778634.4A patent/EP3946287A4/en active Pending
- 2020-03-27 WO PCT/US2020/025217 patent/WO2020198587A1/en not_active Ceased
-
2025
- 2025-02-28 JP JP2025031086A patent/JP2025098027A/ja active Pending